We have identified fundamental similarities among autoimmune conditions – abnormalities in immune cells, inflammation, and organ damage.
NEW YORK (PRWEB) April 10, 2018
Mediaplanet announced the Launch of March’s “Autoimmune Diseases” campaign. With the help of leading sponsor, Houston-based biotechnology company Celltex Therapeutics Corporation, the publication will encourage autoimmune patients to be proactive and seek effective therapies for their chronic conditions.
According to the American Autoimmune Related Diseases Association, 50 million Americans are living with an autoimmune disease. An autoimmune condition develops when the body’s immune system, which is normally tasked with defending against invaders, mistakenly attacks the body’s own healthy cells as foreign invaders. When this happens, the immune cells attack healthy tissue and interfere with normal organ function. Many autoimmune conditions have similar symptoms, which can make them difficult to diagnose, and these symptoms generally fluctuate between periods of mild and severe intensity. There are more than 80 known types of autoimmune conditions, and the treatment approach for most of these diseases focuses on reducing immune system activity.
Within this publication, industry experts weigh in on the need for new treatments for these chronic conditions. Stephen Katz, M.D., Ph.D., Director of the National Institute of Arthritis and Musculoskeletal Skin Diseases at the National Institutes of Health, explains, “We have identified fundamental similarities among autoimmune conditions – abnormalities in immune cells, inflammation, and organ damage.” He continues, “Despite considerable progress, safer and more effective therapies are needed.”
Celltex uses its proprietary technology which isolates, multiplies and banks autologous (one’s own) adult mesenchymal stem cells to be used for regenerative therapy for injuries and chronic pain, as well as a number of conditions, including autoimmune diseases.
“Celltex is pleased to partner with Mediaplanet to spread the message on how adult mesenchymal stem cell therapy can provide life-changing benefits to those suffering from autoimmune diseases,” said Celltex Chief Executive Officer David G. Eller. “Multiple pre-clinical and clinical studies have been performed, or are ongoing, to explore potential opportunities for stem cells to be used in therapy for multiple types of autoimmune diseases, including rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, type 1 diabetes, and psoriasis, among others.”
The print component of “Autoimmune Diseases” is distributed within USA Today in New York, Chicago, Washington, D.C., Philadelphia, Boston, Seattle, and Houston, with a circulation of approximately 250,000 copies and estimated readership of 750,000. The publication will be available at industry conferences, awareness walks, and patient advocacy events across the country. The digital component is distributed nationally through a vast social media strategy and across a network of top news sites and partner outlets. To explore the digital campaign, click here.
Celltex uses proprietary technology that isolates, multiplies and banks autologous (one’s own) adult mesenchymal stem cells (MSCs), to be used in regenerative therapy for injuries and chronic pain, as well as many other conditions, including vascular, degenerative, and autoimmune diseases. Celltex is registered with the U.S. Food and Drug Administration (FDA) as a Human Cells, Tissues, and Cellular and Tissue-based Products (HCT/Ps) establishment that multiplies human cells and cellular products. The Houston-based biotechnology company operates in a state-of-the-art laboratory compliant with Current Good Manufacturing Practice (cGMP) standards as recommended by the FDA for the manufacturing of biological products. To learn more about Celltex, visit http://www.celltexbank.com
Mediaplanet specializes in the creation of content marketing campaigns covering a variety of industries. We tell meaningful stories that educate our audience and position our clients as solution providers. Our unique ability to pair the right leaders with the right readers, through the right platforms, has made Mediaplanet a global content marketing powerhouse. Our award-winning stories have won the hearts of countless readers while serving as a valuable platform for brands and their missions. Just call us storytellers with a purpose. Please visit http://www.mediaplanet.com for more on who we are and what we do.
Maureen McCarthy, Mediaplanet
Megan Flinn, Celltex